Vitamin D pathway gene variants and prostate cancer prognosis.

Publication Type:

Journal Article


The Prostate, Volume 70, Issue 13, p.1448-60 (2010)


2010, 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, Alleles, Case-Control Studies, Center-Authored Paper, DISEASE PROGRESSION, European Continental Ancestry Group, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Prognosis, Proportional Hazards Models, Prostatic Neoplasms, Public Health Sciences Division, Receptors, Calcitriol, Research Trials Office Core Facility - Biostatistics Service, ROC Curve, Shared Resources, Specimen Processing Core Facility, Steroid Hydroxylases


Observational studies linking vitamin D deficiency with increased prostate cancer (PCa) mortality and the pleiotropic anticancer effects of vitamin D in malignant prostate cell lines have initiated trials examining potential therapeutic benefits of vitamin D metabolites. There have been some successes but efforts have been hindered by risk of inducing hypercalcemia. A limited number of studies have investigated associations between variants in vitamin D pathway genes with aggressive forms of PCa. Increased understanding of relevant germline genetic variation with disease outcome could aid in the development of vitamin-D-based therapies.